Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

completed375%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

NCT03653546
unknownphase_2

Phase II Umbrella Study Directed by Next Generation Sequencing

NCT03574402
completedphase_1

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

NCT03360929
completedphase_1

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

NCT02228369

Clinical Trials (4)

Showing 4 of 4 trials
NCT03653546Phase 2

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Completed
NCT03574402Phase 2

Phase II Umbrella Study Directed by Next Generation Sequencing

Unknown
NCT03360929Phase 1

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Completed
NCT02228369Phase 1

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4